3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
20
Lymphoid
4
Gastrointestinal
4
Thoracic
2
Plasma cell
2
Other hematologic neoplasm
2
Myeloid
2
Head & Neck
2
Gynecologic
2
Genitourinary
2
Dermatologic
2
Sarcoma
1
Classical hematology
1
CNS
1
Conditions
Sarcoma
22
Melanoma
6
Histiocytoma, Malignant Fibrous
6
Gastrointestinal Stromal Tumors
5
Osteosarcoma
4
Neoplasm Metastasis
4
Gliosarcoma
4
Neuroblastoma
3
Hemangiosarcoma
3
Chordoma
3
Bone Neoplasms
3
Wilms Tumor
2
Triple Negative Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Lymphoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Liposarcoma
2
Head and Neck Neoplasms
2
Glioblastoma
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Bile Duct Neoplasms
2
Interventions
pembrolizumab
9
Gemcitabine
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Paclitaxel
6
Cisplatin
6
Trastuzumab
5
Irinotecan
5
Doxorubicin
5
Docetaxel
5
Peripheral Blood Stem Cell Transplantation
4
Filgrastim
4
Capecitabine
4
poly ICLC
3
pazopanib
3
liposomal doxorubicin
3
durvalumab
3
atezolizumab
3
Therapeutics
3
Taxes
3
Surveys and Questionnaires
3
Radiation
3
Polymerase Chain Reaction
3
Oncolytic Virotherapy
3
Letrozole
3
Injections
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
Flow Cytometry
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Ipilimumab
×
Sarcoma
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts